Patent infringement: Factor Bioscience sues AstraZeneca, Cellectis over gene-editing technology
Biotech firm Factor Bioscience has filed a lawsuit against Cellectis and AstraZeneca, accusing the companies of allegedly infringing three patents related to its gene-editing technology used in cancer treatments.
The lawsuit, filed in the District federal Court, alleges that Cellectis copied Factor’s technology for designing gene-edited cells for cancer therapies.
Cellectis licenses its gene-editing technology to AstraZeneca for research and development.
"If large multinational pharmaceutical companies are allowed to illegally exploit the research and innovation of companies like Factor, it will have a chilling effect on future innovations and ultimately delay the development of new therapies," Factor CEO Matt Angel said in a statement.
As per reuters, the lawsuit said that Cambridge, Massachusetts-based Factor developed novel techniques for using messenger RNA and proteins, called TALENs, to produce cells to fight cancers like leukemia and lymphoma. Factor alleged that France-based Cellectis copied its mRNA TALEN technology to develop its own leukemia and lymphoma treatments.
United Kingdom-based AstraZeneca agreed in 2023 to license Cellectis' gene-editing technology to help develop therapeutics in fields including oncology, immunology and rare diseases. Factor's lawsuit accused AstraZeneca of violating its patent rights by using Cellectis' technology.
Factor requested an unspecified amount of monetary damages for the alleged infringement.
"Since the discovery of the structure of DNA, there has been interest in developing methods to reprogram cells by editing their genetic code to treat disease and improve health," Factor said in the lawsuit. "There are billions of dollars at stake in being the first company to develop such breakthrough treatments."
The case is Factor Bioscience Inc v. Cellectis Inc, U.S. District Court for the District of Delaware, No. 1:25-cv-01197
For Factor: Robert Cerwinski, Michael Johnson and Lora Green of Gemini Law; Huiya Wu and Linnea Cipriano of Goodwin Procter
For Cellectis and AstraZeneca: attorney information not yet available
Next Story